

RECEIVED  
CENTRAL FAX CENTER

Attorney Docket No.: 6680.200-US

SEP 27 2004

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Johansen et al.

Serial No.: 10/822,020

Group Art Unit: To be assigned

Filed: April 9, 2004

Examiner: To be assigned

For: **PREVENTION OF HYPERINSULINEMIA IN SUBJECTS UNDERGOING  
GROWTH HORMONE (GH) TREATMENT**

**CERTIFICATE OF FACSIMILE TRANSMISSION**  
703-872-9306

Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

Sir:


I hereby certify that the attached correspondence comprising:

1. Preliminary Amendment

was sent to the United States Patent and Trademark Office by telefax to the fax number (703) 872-9306.

Respectfully submitted,

Date: September 27, 2004

  
Csaba Attila Szakolczai  
Novo Nordisk® Pharmaceuticals, Inc.  
100 College Road West  
Princeton, NJ 08540  
(609) 987-5800

**Please Use the following customer number for all correspondence regarding this application.**

**\*23650\***

PATENT TRADEMARK OFFICE

Attorney Docket No.: 6680.200-US

PATENT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Johansen et al.

Application No.: 10/822,020

Group Art Unit: 1653

Filed: April 9, 2004

Examiner: Mayer, Suzanne Marie

For: Prevention of Hyperinsulinemia In Subjects  
Undergoing Growth Hormone (GH) Treatment

RECEIVED  
CENTRAL FAX CENTER

**PRELIMINARY AMENDMENT**

SEP 27 2004

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Prior to the examination of the above-referenced application, please enter the following amendments to the specification.

**Amendments to the Specification** are set forth starting at page 2 of this paper

**Remarks** concerning these amendments are set forth on page 6 of this paper.